A Targeted Treatment for Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease (IBD) is a devastating condition that is currently treatable only with drugs exhibiting significant undesired effects, most notably immunosuppression.

Exploration of the therapeutic drug class of sartans (well known hypertension medicines with excellent safety profiles) for treatment of IBD, represents an effective strategy for bringing a novel, safe, and efficacious treatment option to patients.

Chemical modifications lead to novel inhibitors of pathways and targets in the renin-angiotensin system (RAS) with reduced membrane permeation characteristics, yet retained potency. Furthermore, an innovative biopharmaceutical delivery approach for these candidates has been derived, with high potential for specific targeted delivery of RAS antagonists alone or in combination with other therapeutic agents to inflammatory lesions in the gut.